Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Quest Diagnostics ( (DGX) ) just unveiled an announcement.
On March 9, 2026, Quest Diagnostics’ board elected Timothy Wentworth, former CEO of Walgreens Boots Alliance, Evernorth Health Services and Express Scripts, as an independent director, expanding the board to 11 members. Wentworth, who received standard non‑employee director compensation including a prorated restricted share unit grant, will serve on the Compensation and Leadership Development Committee and the Quality and Compliance Committee.
The appointment brings to Quest a veteran executive with deep experience running large, complex healthcare and consumer-focused organizations, including overseeing Walgreens Boots Alliance’s restructuring ahead of its 2025 sale to Sycamore Partners. His track record in scaling pharmacy benefit management and health services businesses is expected to bolster Quest’s strategic capabilities across health plan, employer and consumer channels, strengthening board oversight of growth, operations and compliance.
The most recent analyst rating on (DGX) stock is a Buy with a $235.00 price target. To see the full list of analyst forecasts on Quest Diagnostics stock, see the DGX Stock Forecast page.
Spark’s Take on DGX Stock
According to Spark, TipRanks’ AI Analyst, DGX is a Neutral.
The score is driven primarily by a solid (but not peak-level) financial profile—improving growth but structurally lower margins and softer cash conversion—supported by constructive price momentum. Earnings-call guidance and operating execution tone are positive, while valuation is fair rather than compelling and near-term margin dilution/reimbursement risks temper upside.
To see Spark’s full report on DGX stock, click here.
More about Quest Diagnostics
Quest Diagnostics Incorporated is a leading U.S. provider of diagnostic information services, connecting clinicians and consumers with laboratory insights to support better health outcomes. The company focuses on delivering smarter, simpler testing and serves roughly half of U.S. physicians and hospitals and about one in three American adults annually through its network of nearly 57,000 employees.
By leveraging its scale in diagnostic testing, Quest seeks to reveal new ways to identify and treat disease, encourage healthier behaviors, and improve healthcare management. The company positions itself as a critical infrastructure player in the healthcare system, supporting health plans, employers and consumers with data-driven insights that help transform lives.
Average Trading Volume: 996,469
Technical Sentiment Signal: Buy
Current Market Cap: $22.03B
For an in-depth examination of DGX stock, go to TipRanks’ Overview page.